Efficacy and Safety of Dual Paclitaxel and Sirolimus Nanoparticle-Coated Balloon

Kenji Kawai; Mohammed Tanjimur Rahman; Ryan Nowicki; Frank D Kolodgie; Atsushi Sakamoto; Rika Kawakami; Takao Konishi; Renu Virmani; Vinod Labhasetwar; Aloke V Finn

doi:10.1016/j.jacbts.2024.02.002

Efficacy and Safety of Dual Paclitaxel and Sirolimus Nanoparticle-Coated Balloon

JACC Basic Transl Sci. 2024 May 1;9(6):774-789. doi: 10.1016/j.jacbts.2024.02.002. eCollection 2024 Jun.

Authors

Affiliations

¹ CVPath Institute, Gaithersburg, Maryland, USA.
² Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
³ Advanced NanoTherapies, Inc, Los Gatos, California, USA.
⁴ University of Maryland, School of Medicine, Baltimore, Maryland, USA.

Abstract

We evaluated a novel dual active pharmaceutical ingredient (API) drug-coated balloon (DCB), which consists of a coating of nanoparticles encapsulating low-dose paclitaxel (PTX) in combination with sirolimus in a synergistic ratio. Compared to the PTX DCB, the dual API DCB demonstrated similar inhibition of cell proliferation in vitro but at a significantly lower total drug dose (over 13 times lower than sirolimus nanoparticles). Animal experiments demonstrated that the dual API DCB is more effective in inhibiting intimal cell proliferation with insignificant downstream embolic effects and myocardial damage compared to the PTX DCB. These findings indicate that dual API DCBs have a high potential to demonstrate improved clinical outcomes and a greater safety profile than the PTX DCBs.

Keywords: downstream embolization; drug-coated balloon; myocardium injury; preclinical research; vascular response.